SLU-PP-332 250mcg

Description

SLU-PP-332 is a synthetic ERR (Oestrogen-Related Receptor) alpha/gamma agonist — a compound discovered at Washington University that activates the transcriptional machinery of exercise adaptation without movement. By directly stimulating ERRα and ERRγ, SLU-PP-332 triggers the gene expression cascade that mitochondrial biogenesis and fast-to-slow muscle fibre transition normally require weeks of endurance training to produce. In animal studies, it increased running capacity by 70% over three weeks, reduced fat mass, and improved metabolic parameters — entirely without exercise. At 250mcg, this is the micro-dose entry point — appropriate for those beginning to explore ERR agonism and assessing individual response. The dose-response profile for SLU-PP-332 in humans is still being characterised through research protocols; conservative initiation is advisable. As with all compounds in this class, purity and dose accuracy are non-negotiable. Each Phalanx tablet is independently verified at 99%+ by Puralytix. The compound is taken orally and benefits from consistent daily administration. Starting at 250mcg allows individual response assessment before escalation. SLU-PP-332’s mechanism operates at the gene expression level — benefits accumulate over weeks of consistent use. Pair with structured cardiovascular training to superimpose exercise-driven adaptation on top of ERR-agonist-driven transcription.